TSE:4530
TSE:4530Pharmaceuticals

Hisamitsu Pharmaceutical (TSE:4530) Margin Improvement Challenges Cautious Growth Narratives

Hisamitsu Pharmaceutical (TSE:4530) has reported Q3 2026 results with revenue of ¥39,571 million and basic EPS of ¥69.15, setting the tone for a quarter where profitability remains firmly in focus. The company has seen quarterly revenue move between ¥35,665 million and ¥44,753 million over the past six reported periods, while basic EPS has ranged from ¥35.13 to ¥111.00. This gives investors a clear view of how the top line and EPS have tracked through recent quarters. With trailing 12 month...
TSE:8078
TSE:8078Trade Distributors

Hanwa (TSE:8078) Valuation Check After Ongoing Share Buyback Activity

Hanwa’s latest share buyback activity Hanwa (TSE:8078) recently reported progress on its ongoing share repurchase, completing the buyback of 284,100 shares, or 0.72% of outstanding stock, for ¥1,950.18 million under its November 2025 authorization. See our latest analysis for Hanwa. Hanwa’s recent buyback news comes after a period of firm share price momentum, with a 90 day share price return of 18.73% and a 1 year total shareholder return of 61.95%. This suggests investors are rewarding the...